Keyword Search Results for "anti-diabetes"

Chisholm, J. W., Goldfine, A. B., Dhalla, A. K., Braunwald, E., Morrow, D. A., Karwatowska-Prokopczuk, E., Belardinelli, L. Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome Diabetes care. 2010;33(6):1163-8. Abstract

Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Price, D. L., Chen, R., Udell, J., Raz, I. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study American heart journal. 2011;162(5):818-825 e6. Abstract

Cavender, Matthew A, Scirica, Benjamin M, Raz, Itamar, Steg, P. G, Hirshberg, Boaz, Davidson, Jaime, Im, KyungAh, Hoffman, Elaine, Braunwald, Eugene, Bhatt, Deepak L Abstract 17270: Outcomes of Patients With Type 2 Diabetes at High Risk of Cardiovascular Events Treated With Saxagliptin: Outcomes by Baseline HgbA1c Circulation. 2013;128(22 Supplement):A17270.

Mosenzon, O., Raz, I., Scirica, B. M., Hirshberg, B., Stahre, C. I., Steg, P. G., Davidson, J., Ohman, P., Price, D. L., Frederich, B., Udell, J. A., Braunwald, E., Bhatt, D. L. Baseline characteristics of patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR) - TIMI 53 Trial Diabetes Metab Res Rev. 2013;NA(NA):NA. Abstract

Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med. 2013;369:1317-1326. Abstract

Scirica, Benjamin M, Raz, Itamar, Cavender, Matthew A, Steg, P. G, Hirshberg, Boaz, Davidson, Jaime, Im, KyungAh, Hoffman, Elaine, Braunwald, Eugene, Bhatt, Deepak L Abstract 17503: Outcomes of Patients With Type 2 Diabetes and Known Congestive Heart Failure Treated With Saxagliptin: Analyses of the SAVOR-TIMI 53 Study Circulation. 2013;128(22 Supplement):A17503.

White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., Cushman, W. C., Zannad, F. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes N Engl J Med. 2013;NA(NA):NA. Abstract

Scirica, Benjamin, Bhatt, Deepak, Braunwald, Eugene, Raz, Itamar, Steg, Philippe, Davidson, Jaime, Cavender, Matthew, Hirshberg, Boaz, Umez-Eronini, Amarachi, Im, Kelly, Jarolim, Petr, Morrow, David Prognostic Implications of Simultaneous Biomarker Assessments in Patients with Type 2 Diabetes Mellitus: Observations from the SAVOR-TIMI 53 TRIAL Journal of the American College of Cardiology. 2014;63(12, Supplement):A1550.

Udell, Jacob A., Scirica, Benjamin, Cavender, Matthew A., Mosenzon, Ofri, Steg, Philippe, Davidson, Jaime, Hirshberg, Boaz, Im, Kyungah, Raz, Itamar, Bhatt, Deepak Baseline Renal Function and Cardiovascular Risk in Patients Treated with Saxagliptin: Observations from the SAVOR-TIMI 53 TRIAL Journal of the American College of Cardiology. 2014;63(12, Supplement):A1523.